Abstract
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.
| Original language | English |
|---|---|
| Article number | e01439 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 62 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2018 |
Fingerprint
Keywords
- KPC
- Klebsiella pneumoniae carbapenemase
- Meropenem
- Pyelonephritis
- Vaborbactam
Cite this
}
Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis. / Weiss, William J.; Pulse, Mark E.; Nguyen, Phung; Peterson, Kelly; Silva, Jessica; Simecka, Jerry W.; Valtierra, David; Sabet, Mojgan; Griffith, David C.
In: Antimicrobial agents and chemotherapy, Vol. 62, No. 1, e01439, 01.2018.Research output: Contribution to journal › Article
TY - JOUR
T1 - Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis
AU - Weiss, William J.
AU - Pulse, Mark E.
AU - Nguyen, Phung
AU - Peterson, Kelly
AU - Silva, Jessica
AU - Simecka, Jerry W.
AU - Valtierra, David
AU - Sabet, Mojgan
AU - Griffith, David C.
PY - 2018/1
Y1 - 2018/1
N2 - The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.
AB - The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.
KW - KPC
KW - Klebsiella pneumoniae carbapenemase
KW - Meropenem
KW - Pyelonephritis
KW - Vaborbactam
UR - http://www.scopus.com/inward/record.url?scp=85039804469&partnerID=8YFLogxK
U2 - 10.1128/AAC.01439-17
DO - 10.1128/AAC.01439-17
M3 - Article
C2 - 29038270
AN - SCOPUS:85039804469
VL - 62
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 1
M1 - e01439
ER -